A reminder that we are presenting this evening at the MelloEventsUK Mello Monday webinar 📅28 July from 6:10pm 🔵Speakers: Jeremy Skillington & Ian O'Connell 💻Virtual Presentation Free Ticket Code: MMSHComp25 Register to attend: tickettailor.com/events/melloev… #POLB #MelloMonday

Our CEO caught up with Joe Lynam at NewstalkFM yesterday morning to discuss all things #POLB 💥POLB 001 - potential to transform cancer care by making cancer immunotherapies safer & allowing their administration to move away from specialist cancer units and into the community

At Poolbeg Pharma we have identified a significant market opportunity in oncology for POLB 001 expected to exceed US$10 billion due to the rapid advancements in bispecific antibody and CAR T cell therapies. Currently, no therapies are approved for the prevention of Cytokine

Our Co-founder and Executive Chair Cathal Friel will be speaking at a panel discussion at the upcoming The Investor Summit event in London 🗓️13 August 2025 🕒16:05 on Porter Tun Stage 🎙️The de-equitisation of Global Markets Cathal will be joined by fellow panellists🗨️ David Belle

Our CEO joined Jo Shorthouse on the Citeline In Vivo podcast, which focuses on perspectives on commercial strategy, deal-making, R&D trends and other key commercial topics. 💡 Jeremy's experience & career highlights 🔬 Overview of Poolbeg Pharma 💊 Lead asset POLB 001: Oral

If you missed our presentation on Monday 28 July, with MelloEventsUK then you can catch up on the full recording below. ✅Company overview 💰Investment case 🔬High value programmes 👉Near-term inflection points Tune in here: youtu.be/XPpbnHvHKNc?t=… #POLB #MelloMonday #Mello

Did you know there is a rapidly growing market for the treatment of metabolic diseases? The World Health Organization (WHO) classifies it as an epidemic, and CDC estimates around 42% of the U.S. population is affected. Obesity impacts nearly every system in the body — from heart disease to cancer — and

A reminder that tomorrow we will be participating in a panel discussion at the The Investor Summit in London. Meet the team at booth 6 and join our panel session at 15:05 on the Upper Sugar stage. 📢 "Immunotherapy and the Future of Oncology: Breakthroughs, Barriers, and the Road

POLB 001 is a potential preventative therapy targeting cancer immunotherapy-induced CRS. Did you know, key opinion leaders were supportive of its significant potential? Check out what the KOL’s had to say… #POLB #Poolbeg #KeyOpinionLeaders #Bispecific #CART #Cancer

Our CEO Jeremy Skillington recorded a short video 📹 during yesterday’s Investor Summit event in London. A huge thank you to our panel speakers Martin Kaiser, Brain White & Ed Bowsher for joining Poolbeg Pharma to discuss Immunotherapy and the Future of Oncology: Breakthroughs,

This week we attended the first The Investor Summit hosted at The Brewery in London, check out our event highlights: 🗣️Panel discussion featuring Shore Capital Markets Healthcare Analyst, Dr Brain White, Professor of Haematology, Consultant Haemato-Oncologist Institute of Cancer Research

Our oral encapsulated GLP-1 programme leverages an advanced delivery system that encapsulates active pharmaceutical ingredients ("API's") using Generally Regarded as Safe ("GRAS") components. This approach targets delivery to specific areas of the gut and into systemic

We have published our latest factsheet! 🚀 Experienced team with a proven track record 🎯 High-value programmes addressing critical unmet medical needs 🤝 Programmes attractive for Pharma partnering 💰 Cash runway into 2027, funding key value inflection points in oncology &

Poolbeg Pharma is a clinical-stage biopharmaceutical company focussed on the development of innovative medicines to address unmet medical needs. We are led by a team dedicated to improving global health and with a track record of success in the pharmaceutical industry. Our high

We're developing an oral encapsulated GLP-1 therapy — designed to transform how metabolic diseases are treated. 🔬 Our cutting-edge delivery system targets specific areas of the gut using a pH-sensitive release mechanism, allowing peptides to be absorbed into systemic

Our CEO Jeremy Skillington spoke with Donald Leggatt from Copia at the The Investor Summit 👉Overview our Poolbeg’s panel discussion 🔵Cancer immunotherapies & side effects 🏥Impact of Cytokine Release Syndrome 🔬POLB 001 – potential to enhance patient safety and thereby

We hosted an exciting panel discussion at the The Investor Summit. Join us in an exciting discussion on “Immunotherapy and the Future of Oncology: Breakthroughs, Barriers and the Road Ahead” featuring our fellow panellists Dr Jeremy Skillington, CEO of Poolbeg Pharma Dr Brian

Our Principal Scientist Liam Tremble will be attending the Myeloma Society’s 22nd Annual Meeting & Exposition on 17 September in Toronto, Canada. This event will provide focus on both the basic, preclinical, and clinical aspects of Myeloma. Meet with Liam to learn more about

“CRS is a big problem” Dr Martin Kaiser, Consultant Haemato-Oncologist The Institute of Cancer Research & Royal Marsden Hospital discusses Cytokine Release Syndrome (CRS) and its impact on cancer immunotherapy administration. Treatment is limited to specialist cancer clinics due to

Tune into our snippet from CEO Jeremy Skillington, who provides a timeline for POLB 001’s milestones ✅Trial to commence before the end 2025 ☑️Interim data in H1 2026 🚀Trial completion by H2 2026 🤝Take datasets, intellectual property to partnering with Big Pharma ➡️ODD